Compare TG Therapeutics Inc (TGTX) vs Trane Technologies plc (TT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Trane Technologies plc — how do they compare? TG Therapeutics Inc trades at $54.41 (market cap $8.32B), while Trane Technologies plc trades at $471.85 (market cap $105.17B). The key difference: Trane Technologies plc is far larger — about 12.6× TG Therapeutics Inc's market cap, and Trane Technologies plc pays a 0.88% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | TT | |
|---|---|---|
Market Cap | $8.32B | $105.17B |
Volume | 1,001,204 | 1,040,183 |
Sector | Health | Industrials |
52-Week High | $59.06 | $503.46 |
52-Week Low | $26.94 | $376.43 |
Typical Hold Time | 16 Days | — |
Enterprise Value | $8.52B | $108.47B |
Dividend Yield | — | 0.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics trades at $54.34, down 1.68% today, with a bullish technical outlook supported by moving averages. The company shows strong profitability with 55.22% net income margin and 100.28% ROE, though recent quarters saw EPS misses. Revenue guidance for 2026 is raised to $950M for BRIUMVI, with institutional buying interest from major banks. A shareholder investigation by Kuehn Law presents legal overhang.
Outlook remains positive given analyst consensus target of $80.50 (48% upside) and buyout speculation. Key risks include ongoing legal scrutiny and reliance on BRIUMVI's market share growth. The stock offers growth potential but requires monitoring of legal developments and competitive pressures in the MS treatment space.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Trane Technologies plc
Trane Technologies plc is a global climate solutions company that designs, manufactures, and services heating, ventilation, and air conditioning (HVAC) and transport refrigeration equipment under its Trane and Thermo King brands.
Read more on TT →
